GlassScriptPhysician profile
Sheena B Patel
NPI 1235496142
$88,289.78
in general payments reported to CMS, 2019-2025
43 companies · $43K in 2025
The $43K reported for 2025 was more than what 97% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,671 · 2020: $5,999 · 2021: $5,836 · 2022: $16K · 2023: $8,191 · 2024: $3,538 · 2025: $43K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $29K · Travel and Lodging: $12K · Food and Beverage: $8,684 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $4,750 · Education: $208.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $28,910.00 |
| Travel and Lodging | $12,144.40 |
| Food and Beverage | $8,683.90 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $4,750.00 |
| Education | $207.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $42,509.96 | 2024-2025 | Iqirvo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31,588.22 | 2019-2025 | Trulance, Xifaxan, Plenvu |
| Abbvie INC. | $5,251.19 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $2,014.50 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Lucid Diagnostics INC. | $1,247.93 | 2021-2024 | |
| Janssen Biotech, INC. | $797.76 | 2019-2025 | Stelara, Simponi, Simponi Aria |
| Genzyme Corporation | $396.75 | 2022-2025 | |
| Gilead Sciences, INC. | $395.75 | 2019-2024 | Livdelzi |
| Qol Medical, LLC | $357.01 | 2020-2024 | Sucraid, Sucraid |
| Boston Scientific Corporation | $353.82 | 2019-2024 | Compliance Endokit, Exalt Model D |
| Celgene Corporation | $325.90 | 2021-2023 | Zeposia |
| Daiichi Sankyo INC. | $300.05 | 2019-2025 | Injectafer |
| Nestle Healthcare Nutrition INC. | $279.91 | 2020-2023 | |
| Intercept Pharmaceuticals, INC. | $263.13 | 2019-2022 | |
| Evoke Pharma, INC. | $241.43 | 2023-2024 | Gimoti |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $240.55 | 2021-2024 | Dificid |
| Pfizer INC. | $221.20 | 2019-2024 | |
| Allergan, INC. | $179.91 | 2019 | |
| Ferring Pharmaceuticals INC. | $147.18 | 2024 | Rebyota |
| Ardelyx, INC. | $115.67 | 2022-2024 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $103.82 | 2020-2024 | |
| Regeneron Pharmaceuticals, INC. | $102.58 | 2023 | Dupixent |
| Philips North America LLC | $88.99 | 2022 | |
| Organon LLC | $81.88 | 2021-2025 | Renflexis, Hadlima |
| Lilly USA, LLC | $77.87 | 2024-2025 | Omvoh |
| Celltrion USA INC. | $73.29 | 2023-2025 | Zymfentra, Vegzelma, Yuflyma |
| Braintree Laboratories, INC. | $69.33 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $66.00 | 2022-2025 | Dupixent |
| Madrigal Pharmaceuticals | $59.63 | 2024-2025 | Rezdiffra, Resmetirom |
| E.R. Squibb & Sons, L.L.C. | $58.82 | 2021 | |
| Phathom Pharmaceuticals, INC. | $47.30 | 2024-2025 | Voquezna |
| Aimmune Therapeutics, INC. | $36.02 | 2023-2025 | Vowst |
| Shield Therapeutics INC | $31.60 | 2024 | |
| Abbott Laboratories | $23.49 | 2023 | Mitraclip |
| Alfasigma USA, INC. | $23.01 | 2020 | |
| Alexion Pharmaceuticals, INC. | $16.30 | 2019 | |
| Medtronic, INC. | $15.86 | 2024 | Gi Genius |
| Sandoz INC. | $15.63 | 2024 | Hyrimoz |
| Amgen INC. | $15.63 | 2021 | |
| Redhill Biopharma INC. | $14.32 | 2021 | |
| Shire North American Group INC | $13.82 | 2019 | |
| Amag Pharmaceuticals, INC. | $13.71 | 2019 | |
| Alnylam Pharmaceuticals INC. | $13.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheena Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.